Get the Right Care
Community Involvement
Combining Medications and Surgery in Weight Loss: A Changing Approach
Obesity treatment is changing. Medication and bariatric surgery are no longer viewed only as competing choices. Current research supports a more individualized model in which each treatment can serve a different purpose over time.
GLP-1 medications such as semaglutide reduce appetite and can lead to reductions in body weight. They may be an option for eligible adults, including people with severe obesity, but medication is not suitable or sufficient for everyone. Common side effects can include nausea, and individual suitability should be assessed by qualified healthcare providers.
New research presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2026 annual meeting suggests that using weight-loss medications before bariatric surgery may strengthen overall results rather than limit them. Individuals who start treatment with glucagon-like peptide-1 receptor agonists and later proceed to surgery can achieve significant additional weight loss, with bariatric surgery building on the modest early reductions seen with medication alone.
The study examined more than 6,700 bariatric surgery patients who were prescribed semaglutide or a similar medication with additional GIP agonist effects during the six months before surgery. These patients lost approximately 8% of their starting weight before their procedures, with total weight loss later exceeding 25% after gastric bypass and reaching approximately 20% after sleeve gastrectomy. Although patients who went directly to surgery lost more weight from the procedure itself, the findings suggest that prior medication use did not compromise surgical effectiveness. However, they do not establish that taking weight-loss medication before surgery leads to better long-term results than surgery alone.
GLP-1 medications have transformed obesity care by helping reduce appetite and providing support early weight loss. For many people, these therapies provide a more accessible first step, compared to surgery. However, they are not always sufficient on their own. Bariatric procedures such as gastric bypass and sleeve gastrectomy continue to offer the most consistent and durable weight-loss outcomes, according to the research available at the moment. Their metabolic benefits may include better control of diabetes, hypertension and other related health conditions.
Rather than competing, these treatments are increasingly viewed as complementary tools along a care pathway. Early use of medication may help patients begin weight loss before surgery, while surgery builds on those changes and supports longer-term results compared to medication alone.
At the same time, evidence suggests that using medications before surgery does not consistently enhance long-term weight outcomes compared with surgery alone. A 2025 study found that the early advantage from combination therapy did not persist beyond three months after surgery. Timing, medical history, body mass index and previous treatment response remain important considerations.
Obesity is now recognized as a chronic condition, requiring ongoing management, even before other health conditions associated with obesity arise, rather than a single intervention. Some patients start weight-loss medications after surgery, particularly when weight loss is less than expected or weight regain occurs.
A 2025 US study found that 14% of 112,858 people began GLP-1 treatment after bariatric surgery. Many started several years after their procedure, once these new medications became available for use. These findings reflect a growing role for combined, long-term treatment approaches, but they do not mean medication is required for most patients.
Recent expert reviews emphasize a broader shift toward integrated treatment models, where surgery and pharmacotherapy are used together rather than in isolation. This approach mirrors care for other chronic diseases, where treatment is adjusted as a patient’s health and response change.
For patients, this represents a meaningful change in how weight loss is approached. It is no longer simply a question of choosing between medication and surgery, but of understanding how different tools can be used over time.
Clinique Michel Gagner offers medical weight-management consultations, nutrition support, GLP-1 treatment and minimally invasive bariatric surgery. Our specialists assess your health, previous treatment and goals before providing individualized guidance.
Review our treatment fees, then complete the patient questionnaire to learn which approach may be appropriate for you.
1. American Society for Metabolic and Bariatric Surgery (ASMBS). (2026, May 5). New study finds metabolic and bariatric surgery after GLP‑1 treatment significantly boosts weight loss (Presented at ASMBS Annual Meeting 2026).
2. Mathur, V., Wasden, K., Shin, T. H., et al. (2025). Neoadjuvant semaglutide, bariatric surgery weight loss, and overall outcomes. JAMA Surgery, 160(5), 594–596.
3. Kim, M., Schweitzer, M. A., Kim, J. S., Alexander, G. C., & Mehta, H. B. (2025). Use of glucagon-like peptide-1 receptor agonists among individuals undergoing bariatric surgery in the US. JAMA Surgery.
4. Pournaras, D. J., Lingvay, I., & Sumithran, P. (2024). Better together: antiobesity medications and bariatric surgery for the management of obesity. British Journal of Surgery, 111(12), znae294.
